These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7606564)

  • 1. Effectiveness and economy of low-dose ondansetron.
    Walton SC; Koenig TJ
    Am J Health Syst Pharm; 1995 Mar; 52(5):546-7. PubMed ID: 7606564
    [No Abstract]   [Full Text] [Related]  

  • 2. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
    Tanneberger S; Lelli G; Martoni A; Piana E; Pannuti F
    J Chemother; 1992 Oct; 4(5):326-31. PubMed ID: 1479424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron in the treatment of nausea and vomiting. Introduction.
    Marschner N
    Anticancer Drugs; 1993 Dec; 4 Suppl 2():3-7. PubMed ID: 8136513
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quality of life in oncology. Importance of optimal control of nausea/vomiting induced by antineoplastic agents].
    Soins; 1994 Oct; (589):23-4. PubMed ID: 7676292
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
    Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
    Berard CM; Mahoney CD
    Am J Health Syst Pharm; 1995 Sep; 52(17):1879-85. PubMed ID: 8528849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
    Stewart DJ; Dahrouge S; Coyle D; Evans WK
    J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global experience with ondansetron and future potential.
    Butcher ME
    Oncology; 1993; 50(3):191-7. PubMed ID: 8459991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
    Dranitsaris G; Mazzarello S; Smith S; Vandermeer L; Bouganim N; Clemons M
    Support Care Cancer; 2016 Apr; 24(4):1563-9. PubMed ID: 26381427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
    Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
    Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment: Ondansetron for treating nausea and vomiting in the poisoned patient.
    Forster ER; Palmer JL
    Ann Pharmacother; 1994 Oct; 28(10):1203-4. PubMed ID: 7841589
    [No Abstract]   [Full Text] [Related]  

  • 20. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
    Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
    J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.